2023-506156-25-00CompletedPhase 1/2
A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 8 Nov 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 26 Sept 2024
- Start date
- 13 Nov 2020
- Lead sponsor
- Institut Gustave Roussy
- Diseases
- Liver and biliary tract cancer
- EU CT number
- 2023-506156-25-00
- EudraCT number
- 2020-003766-40
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 30
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gustave Roussy | Villejuif | France | Completed |
| Service Hospitalier Frédéric Joliot - Commissariat à Energie Atomique | Villejuif | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.